Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma
Status:
Terminated
Trial end date:
2018-12-17
Target enrollment:
Participant gender:
Summary
The intent of the study is to assess the antitumor activity of PHA-848125AC as second-line
treatment in patients with recurrent or metastatic, unresectable thymic carcinoma previously
treated with chemotherapy.